Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by MILIND JAVLE and FUNDA MERIC-BERNSTAM.
MILIND JAVLE
Connection Strength
3.427
FUNDA MERIC-BERNSTAM
  1. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors. Oncologist. 2024 Apr 04; 29(4):e514-e525.
    View in: PubMed
    Score: 0.246
  2. Co-Clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts. Cancer Discov. 2024 Feb 15.
    View in: PubMed
    Score: 0.244
  3. Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing. J Immunother Precis Oncol. 2024 Feb; 7(1):7-17.
    View in: PubMed
    Score: 0.243
  4. Convergent MAPK pathway alterations mediate acquired?resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma. J Hepatol. 2024 Feb; 80(2):322-334.
    View in: PubMed
    Score: 0.239
  5. Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma. J Immunother Precis Oncol. 2022 Feb; 5(1):26-30.
    View in: PubMed
    Score: 0.212
  6. Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study. Cancer Discov. 2022 02; 12(2):402-415.
    View in: PubMed
    Score: 0.206
  7. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021 09; 22(9):1290-1300.
    View in: PubMed
    Score: 0.204
  8. Next generation sequencing for biliary tract cancers. Expert Rev Gastroenterol Hepatol. 2021 May; 15(5):471-474.
    View in: PubMed
    Score: 0.199
  9. Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. Sci Rep. 2020 12 16; 10(1):22087.
    View in: PubMed
    Score: 0.196
  10. Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clin Cancer Res. 2020 04 15; 26(8):1924-1931.
    View in: PubMed
    Score: 0.183
  11. Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. JCO Precis Oncol. 2019; 3.
    View in: PubMed
    Score: 0.181
  12. Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype. JCO Precis Oncol. 2018 Nov; 2:1-12.
    View in: PubMed
    Score: 0.169
  13. Biliary cancer: Utility of next-generation sequencing for clinical management. Cancer. 2016 Dec 15; 122(24):3838-3847.
    View in: PubMed
    Score: 0.146
  14. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One. 2014; 9(12):e115383.
    View in: PubMed
    Score: 0.129
  15. KRAS Allelic Variants in Biliary Tract Cancers. JAMA Netw Open. 2024 May 01; 7(5):e249840.
    View in: PubMed
    Score: 0.062
  16. RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study. Mol Cancer. 2024 03 26; 23(1):64.
    View in: PubMed
    Score: 0.061
  17. BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study. NPJ Precis Oncol. 2023 Feb 18; 7(1):19.
    View in: PubMed
    Score: 0.057
  18. Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors. JCO Precis Oncol. 2022 02; 6:e2100197.
    View in: PubMed
    Score: 0.053
  19. The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. Hepatology. 2022 02; 75(2):297-308.
    View in: PubMed
    Score: 0.052
  20. Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens. J Immunother Precis Oncol. 2021 May; 4(2):45-52.
    View in: PubMed
    Score: 0.050
  21. Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients. JCO Precis Oncol. 2020; 4.
    View in: PubMed
    Score: 0.047
  22. Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients. Hepatobiliary Surg Nutr. 2019 Dec; 8(6):604-614.
    View in: PubMed
    Score: 0.045
  23. Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNA. JCO Precis Oncol. 2019; 3.
    View in: PubMed
    Score: 0.045
  24. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. Cancer. 2019 02 01; 125(3):463-472.
    View in: PubMed
    Score: 0.042
  25. Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers. Mol Cancer Ther. 2018 07; 17(7):1595-1601.
    View in: PubMed
    Score: 0.041
  26. Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Oncotarget. 2017 Oct 20; 8(50):87163-87173.
    View in: PubMed
    Score: 0.039
  27. Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. Clin Cancer Res. 2017 Sep 15; 23(18):5648-5656.
    View in: PubMed
    Score: 0.038
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.